{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Petros Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"PTPI"},"Address":{"label":"Address","value":"1185 AVENUE OF THE AMERICAS,3RD FLOOR, NEW YORK, New York, 10036, United States"},"Phone":{"label":"Phone","value":"+1 973 242-0005"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Prescription Medications segment. The Prescription Medications segment consists primarily of operations related to Stendra, which is sold generally in the United States, and H100 for the treatment of Peyronie's disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.petrospharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"John Shulman","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}